New pages

14:1114:11, 13 April 2025 Enhertu (hist | edit) [6,505 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=fam-trastuzumab deruxtecan-nxki |aOrAn=an |drugClass=Anti-HER2 antibody |indicationType=treatment |indication=Unresectable or metastatic HER2-positive and HER2-low breast cancer. Also for treating Unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC) and Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. |hasBlackBoxWarning=Ye...")
13:3513:35, 13 April 2025 Lemborexant (hist | edit) [5,310 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Lemborexant |aOrAn=a |drugClass=Dual Orexin Receptor Antagonist (DORA) |indicationType=treatment |indication=adult patients with insomnia |adverseReactions=Somnolence, Fatigue, Headache, Abnormal dreams, Sleep paralysis, and Hypnagogic hallucinations. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition...")
13:1713:17, 13 April 2025 Lumateperone tosylate (hist | edit) [4,573 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Lumateperone Tosylate |aOrAn=an |drugClass=Atypical Antipsychotic |indicationType=treatment |indication=schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥5% and twice the rate of placebo): somnolence/sedation, dry mouth. |blackBoxWarningTitle=Increased Mortalit...")
13:0213:02, 13 April 2025 Brilliant Blue G Ophthalmic Solution (hist | edit) [4,137 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Brilliant Blue G |aOrAn=a |drugClass=Disclosing Agent |indicationType=procedure |indication=staining the internal limiting membrane (ILM) during ophthalmic surgery. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaLIADAdult=Inject TissueBlue 0.025% directly into a Balanced Salt Solutio...")
12:5112:51, 13 April 2025 Padcev (hist | edit) [6,010 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Enfortumab vedotin-ejfv |aOrAn=an |drugClass=Antineoplastic Agent |indicationType=treatment |indication=Locally advanced or metastatic urothelial cancer (mUC) in adult patients and Locally advanced or metastatic urothelial cancer (mUC) in adult patients who are ineligible for cisplatin-containing chemotherapy. |hasBlackBoxWarning=Yes |adverseReactions=Rash, alopecia, dry skin, pruritus, perip...")
12:2912:29, 13 April 2025 Golodirsen (hist | edit) [4,122 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Golodirsen |aOrAn=an |drugClass=Antisense oligonucleotide |indicationType=treatment |indication=Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. |adverseReactions=Common Adverse Reactions (≥20% incidence): Headache, fever, fall, abdominal pain, nasopharyngitis, cough, vomiting, and nausea. |blackBoxWarningTitle=''...")
12:1212:12, 13 April 2025 Voxelotor (hist | edit) [5,316 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Voxelotor |aOrAn=a |drugClass=Hemoglobin S polymerization inhibitor |indicationType=treatment |indication=sickle cell disease (SCD) in adults and pediatric patients aged 4 years and older. |adverseReactions=Common Adverse Reactions (≥10% incidence): Headache, diarrhea, abdominal pain, nausea, rash, and pyrexia. Note: As of September 2024, Pfizer has voluntarily withdrawn Oxbryta from al...")
11:5111:51, 13 April 2025 Cenobamate (hist | edit) [7,196 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=cenobamate |aOrAn=a |drugClass=Sodium Channel Inhibitor |indicationType=treatment |indication=partial-onset seizures in adult patients. |adverseReactions=dizziness, somnolence, fatigue, headache, nausea, constipation, balance disorder, and rash. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content...")

14:3514:35, 12 April 2025 Flurpiridaz F 18 (hist | edit) [23,419 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Flurpiridaz F 18 in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of Flurpi...")
13:4513:45, 12 April 2025 Xanomeline and trospium chloride (hist | edit) [46,444 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Xanomeline and trospium chloride in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–...")
13:4413:44, 12 April 2025 Lebrikizumab-lbkz (hist | edit) [39,416 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Lebrikizumab-lbkz in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Suppo...")
13:4413:44, 12 April 2025 Axatilimab-csfr (hist | edit) [23,789 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Axatilimab-csfr in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Support...")
13:4313:43, 12 April 2025 Nemolizumab-ilto (hist | edit) [24,525 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Nemolizumab-ilto in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Suppor...")
13:4213:42, 12 April 2025 Crovalimab-akkz (hist | edit) [50,869 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Crovalimab-akkz in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Support...")

16:3716:37, 11 April 2025 Nirmatrelvir and ritonavir (hist | edit) [66,238 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=nirmatrelvir and ritonavir |aOrAn=a |drugClass=strong CYP3A inhibitor, |indicationType=treatment |indication=nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro: also referred to as 3CLpro or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor,that is FDA approved for the treatment of mild-to-moderate coronavirus disease 2019 (COVI...")
11:3311:33, 11 April 2025 Nirmatrelvir, ritonavir (hist | edit) [66,382 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=nirmatrelvir and ritonavir |aOrAn=a |drugClass=strong CYP3A inhibitor, |indicationType=treatment |indication=PAXLOVID is a nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro: also referred to as 3CLpro or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor,that is FDA approved for the treatment of mild-to-moderate coronavirus dise...")
01:4301:43, 11 April 2025 Drug coated balloon (hist | edit) [75,458 bytes] Parth Vikram Singh (talk | contribs) (Created page with "__NOTOC__ thumb|right|250px|An example of a drug-eluting stent. This is the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System, which releases [[paclitaxel.]] {{SI}} {{CMG}} ==Overview== In cardiology, a '''drug-eluting stent''' is a stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents s...")

19:4919:49, 10 April 2025 Zanidatamab-hrii (hist | edit) [24,381 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=zanidatamab-hrii |aOrAn=a |drugClass=bispecific HER2-directed antibody |indicationType=treatment |indication=ZIIHERA is a bispecific HER2-directed antibody that is FDA approved for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. |adverseReactions=*...")
11:5311:53, 10 April 2025 Givinostat Hydrochloride (hist | edit) [14,877 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=givinostat |aOrAn=an |drugClass=inhibits class I and class II histone deacetylases (HDACs) and several pro-inflammatory cytokines |indicationType=treatment |indication=of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. |adverseReactions=*Hematological Changes *Increased Triglycerides *Gastrointestinal Disturbances *QTc Prolongation |blackBoxWarningTitle='...")
10:3310:33, 10 April 2025 Sotatercept-csrk (hist | edit) [18,496 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName= Alara Ece Dagsali, M.D. |aOrAn=an |drugClass=activin signalling inhibitor |indicationType=treatment |indication=of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. |adverseReactions=*Erythrocytosis *Severe Thr...")
10:1410:14, 10 April 2025 Givinostat (hist | edit) [2,643 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Givinostat in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Us...")
09:5609:56, 10 April 2025 Duvyzat (hist | edit) [4,812 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=givinostat |aOrAn=a |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Duvyzat in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Labe...")
06:0306:03, 10 April 2025 Nogapendekin alfa inbakicept-pmln (hist | edit) [16,208 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=nogapendekin alfa inbakicept-pmln |aOrAn=an |drugClass=interleukin-15 (IL-15) receptor agonist |indicationType=treatment |indication=of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. |adverseReactions=The most common (≥15%) adverse reactions, were increased creatinine, dysuria, hematuri...")

15:1515:15, 8 April 2025 Givosiran (hist | edit) [7,932 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Givosiran |aOrAn=a |drugClass=Small interfering RNA (siRNA) agent |indicationType=treatment |indication=acute hepatic porphyria (AHP) in adults. |adverseReactions=nausea, injection site reactions, fatigue, and elevated liver enzymes. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaLIADAd...")
09:5609:56, 8 April 2025 Levacetylleucine (hist | edit) [22,144 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=levacetylleucine |indicationType=treatment |indication=AQNEURSA is FDA approved for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥5% and greater than placebo) are abdominal pain, dysphagia, upper respiratory tract infections, and vomiting. |...")

15:2015:20, 7 April 2025 Mavorixafor (hist | edit) [31,950 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Mavorixafor in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported U...")
14:2914:29, 7 April 2025 Adakveo (hist | edit) [5,828 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |genericName=Crizanlizumab-tmca |aOrAn=a |drugClass=Monoclonal Antibody |indicationType=prophylaxis |indication=vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. |adverseReactions=Nausea, Arthralgia (joint pain), Back pain, and Pyrexia (fever). |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition...")
10:1010:10, 7 April 2025 Imetelstat (hist | edit) [36,430 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Imetelstat in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Us...")
03:4003:40, 7 April 2025 Berdazimer (hist | edit) [15,716 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |indicationType=treatment |indication=abc |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Berdazimer in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use''...")

10:3310:33, 6 April 2025 Elafibranor (hist | edit) [45,146 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Elafibranor in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-...")
09:1809:18, 6 April 2025 SOFDRA (hist | edit) [24,783 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=sofpironium |aOrAn=an |indicationType=treatment |indication=SOFDRA is an anticholinergic FDA approved for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. |adverseReactions=• Most common adverse reactions (incidence ≥2%) are:  dry mouth,  vision blurred,  application site pain,  application site erythema,  mydriasis...")
07:1507:15, 6 April 2025 Sofpironium (hist | edit) [21,666 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=sofpironium |aOrAn=an |indicationType=treatment |indication=SOFDRA is an anticholinergic approved for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is li...")

10:2310:23, 5 April 2025 Ensifentrine (hist | edit) [29,428 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=ensifentrine |aOrAn=a |indicationType=treatment |indication=OHTUVAYRE is a phosphodiesterase 3 (PDE3) inhibitor and phosphodiesterase 4 (PDE4) inhibitor approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'...")

17:1317:13, 3 April 2025 Vorasidenib (hist | edit) [40,798 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Vorasidenib in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-...")

17:2017:20, 2 April 2025 Palopegteriparatide (hist | edit) [48,352 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Palopegteriparatide in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Gu...")

11:2811:28, 1 April 2025 Seladelpar (hist | edit) [35,835 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Seladelpar in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of Seladelpar i...")

03:3703:37, 31 March 2025 Lazertinib (hist | edit) [49,618 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=Lazertinib |aOrAn=a |indicationType=treatment |indication=LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. |adverseReactions=The following...")

16:0016:00, 30 March 2025 Landiolol (hist | edit) [950 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Landiolol in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Su...")
11:1011:10, 30 March 2025 Acoramidis (hist | edit) [16,592 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=acoramidis |aOrAn=a |drugClass=transthyretin stabilizer |indicationType=treatment |indication=ATTRUBY is a transthyretin stabilizer that is FDA approved for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. |adverseReactions=• There was a higher frequency of gas...")

15:1415:14, 28 March 2025 Post-thrombotic syndrome surgical therapy (hist | edit) [1,813 bytes] Badgettrg (talk | contribs) (Created page with "__NOTOC__ {{Post-thrombotic syndrome}} Endovascular stenting of the iliac vein may help.<ref name="pmid29292114 ">{{cite journal | last=Rossi | first=Fabio H. | last2=Kambara | first2=Antonio M. | last3=Izukawa | first3=Nilo M. | last4=Rodrigues | first4=Thiago O. | last5=Rossi | first5=Cybelle B. | last6=Sousa | first6=Amanda G. | last7=Metzger | first7=Patrick B. | last8=Thorpe | first8=Patricia E. | title=Randomized double-blinded study comparing medical treatment ve...")
13:1213:12, 28 March 2025 Revuforj (hist | edit) [36,561 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=Revumenib |aOrAn=a |drugClass=Menin inhibitor |indicationType=treatment |indication=Revumenib is a menin inhibitor that is FDA approved for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. |hasBlackBoxWarning=Yes |adverseReactions=Common adverse reactions include hemorrhage, nausea, ph...")
02:4602:46, 28 March 2025 Crinecerfont (hist | edit) [45,840 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |OTC=Yes |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Crinecerfont in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of C...")

13:5213:52, 27 March 2025 Revumenib (hist | edit) [24,967 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=Revumenib |aOrAn=a |drugClass=Menin inhibitor |indicationType=treatment |indication=Revumenib is a menin inhibitor that is FDA approved for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. |hasBlackBoxWarning=Yes |adverseReactions=Common adverse reactions include Bleedin...")

12:4112:41, 23 March 2025 Cefiderocol (hist | edit) [6,676 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid AfkhamiArdakani |genericName=Cefiderocol |aOrAn=a |drugClass=Siderophore Cephalosporin Antibiotic |indicationType=treatment |indication=Complicated Urinary Tract Infections (cUTIs), Hospital-Acquired Bacterial Pneumonia (HABP), and Ventilator-Associated Bacterial Pneumonia (VABP) in adult patients. |hasBlackBoxWarning=Yes |adverseReactions=Diarrhea, Infusion site reactions, Constipation, Rash, Candidiasis (including...")

00:4700:47, 21 March 2025 Zanubrutinib (hist | edit) [6,355 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Zanubrutinib |aOrAn=a |drugClass=Bruton's Tyrosine Kinase (BTK) Inhibitor |indicationType=treatment |indication=Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Waldenström's Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), and Follicular Lymphoma (FL) in adults. |adverseReactions=Decreased neutrophil count, Upper respiratory tract infection,...")

10:5610:56, 20 March 2025 Reblozyl (hist | edit) [5,813 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Luspatercept-aamt |aOrAn=an |drugClass=Erythroid Maturation Agent |indicationType=treatment |indication=anemia in adult patients. More specifically anemia due to Beta Thalassemia, Myelodysplastic Syndromes (MDS), MDS with Ring Sideroblasts (MDS-RS) or Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). |adverseReactions=Fatigue, Headache, Musc...")
10:2010:20, 20 March 2025 Vadadustat (hist | edit) [19,544 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=vadadustat |indicationType=treatment |indication=VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. |hasBlackBoxWarning=Yes |adverseReactions=*VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) *Targeting a hemoglobin lev...")

20:5820:58, 18 March 2025 Danicopan (hist | edit) [29,524 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Danicopan |aOrAn=a |drugClass=medication |indicationType=treatment |indication=VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). |hasBlackBoxWarning=Yes |adverseReactions=*Serious Infections Caused by Encapsulated Bacteria *Hepatic Enzyme Increase *Hyperl...")
20:3620:36, 18 March 2025 Ceftobiprole medocaril sodium (hist | edit) [36,115 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=ceftobiprole medocaril sodium |aOrAn=a |drugClass=beta-lactam class of antibiotics |indicationType=treatment |indication='''1.1 Staphylococcus aureus Bloodstream Infection (Bacteremia)''' ZEVTERA is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infection (bacteremia) (SAB), including those with right-sided infective endocarditis, caused by me...")
19:4819:48, 18 March 2025 Pegulicianine (hist | edit) [17,295 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=User:AED |genericName=pegulicianine |aOrAn=a |drugClass=diagnostic imaging agent |indicationType=diagnosis |indication=LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. |hasBlackBoxWarning=Yes |adverseReactions=*Anaphylaxis and Other Serious Hyp...")

New pages

13 April 2025

12 April 2025

11 April 2025

10 April 2025

8 April 2025

7 April 2025

6 April 2025

5 April 2025

3 April 2025

2 April 2025

1 April 2025

31 March 2025

30 March 2025

28 March 2025

27 March 2025

23 March 2025

21 March 2025

20 March 2025

18 March 2025

Navigation menu

Search